Summary of Study ST002183

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001390. The data can be accessed directly via it's Project DOI: 10.21228/M82117 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002183
Study TitleIndividualized exercise intervention for people with multiple myeloma improves quality of life in a randomized controlled trial
Study SummaryAlthough new treatments have improved survival for multiple myeloma (MM), quality of life remains poor for people with this incurable cancer. We conducted a multi-site randomized, waitlist-controlled trial of an individualized exercise program for people at all stages of MM (n=60). Compared to the waitlist control group, participants of the 12-week intervention had significant improvement in health-related quality of life, mediated through improved MM symptoms, cardiorespiratory fitness and bone pain, with were mostly maintained at follow-up (up to 12 months). Exploratory plasma metabolomics and lipidomics was conducted to delineate molecular mechanisms and biomarkers
Institute
QIMR Berghofer Medical Research Institute
LaboratoryPrecision & Systems Biomedicine
Last NameStoll
First NameThomas
Address300 Herston Road
Emailthomas.stoll@qimrberghofer.edu.au
Phone+61 7 3845 3992
Submit Date2022-06-01
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2024-02-05
Release Version1
Thomas Stoll Thomas Stoll
https://dx.doi.org/10.21228/M82117
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001390
Project DOI:doi: 10.21228/M82117
Project Title:Individualized exercise intervention for people with multiple myeloma improves quality of life in a randomized controlled trial
Project Type:MS untargeted metabolomics analysis
Project Summary:Although new treatments have improved survival for multiple myeloma (MM), quality of life remains poor for people with this incurable cancer. We conducted a multi-site randomized, waitlist-controlled trial of an individualized exercise program for people at all stages of MM (n=60). Compared to the waitlist control group, participants of the 12-week intervention had significant improvement in health-related quality of life, mediated through improved MM symptoms, cardiorespiratory fitness and bone pain, with were mostly maintained at follow-up (up to 12 months). Exploratory plasma metabolomics and lipidomics was conducted to delineate molecular mechanisms and biomarkers
Institute:QIMR Berghofer Medical Research Institute
Laboratory:Precision & Systems Biomedicine
Last Name:Stoll
First Name:Thomas
Address:300 Herston Road, Herston, Queensland, 4006, Australia
Email:thomas.stoll@qimrberghofer.edu.au
Phone:+61 7 3845 3992

Subject:

Subject ID:SU002269
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Mammals

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Group Time_point
SA209692HP_BlankNegControlExtraction_04Blank Blank
SA209693HP_BlankNegControlExtraction_03Blank Blank
SA209694HP_BlankNegControlExtraction_01Blank Blank
SA209695HP_BlankNegControlExtraction_06Blank Blank
SA209696HP_BlankNegControlExtraction_02Blank Blank
SA209697HP_BlankNegControlExtraction_05Blank Blank
SA209746MM036_0_pE1exercise -
SA209747MM055_0_pE1exercise -
SA209748MM040_0_pE1exercise -
SA209749MM051_0_pE1exercise -
SA209750MM050_0_pE1exercise -
SA209751MM044_0_pE1exercise -
SA209752MM039_0_pE1exercise -
SA209753MM032_0_pE1exercise -
SA209754MM058_0_pE1exercise -
SA209755MM041_0_pE1exercise -
SA209756MM035_0_pE1exercise -
SA209757MM022_0_pE1exercise -
SA209758MM003_0_p1exercise -
SA209759MM014_0_p1exercise -
SA209760MM008_0_p1exercise -
SA209761MM011_0_p1exercise -
SA209762MM004_0_p1exercise -
SA209763MM010_0_p1exercise -
SA209764MM027_0_pE1exercise -
SA209765MM026_0_pE1exercise -
SA209766MM058_1_pE1exercise 1
SA209767MM051_1_pE1exercise 1
SA209768MM050_1_pE1exercise 1
SA209769MM036_1_pE1exercise 1
SA209770MM055_1_pE1exercise 1
SA209771MM041_1_pE1exercise 1
SA209772MM044_1_pE1exercise 1
SA209773MM040_1_pE1exercise 1
SA209774MM039_1_pE1exercise 1
SA209775MM022_1_pE1exercise 1
SA209776MM008_1_pE1exercise 1
SA209777MM010_1_pE1exercise 1
SA209778MM032_1_pE1exercise 1
SA209779MM014_1_pE1exercise 1
SA209780MM011_1_pE1exercise 1
SA209781MM035_1_pE1exercise 1
SA209782MM027_1_pE1exercise 1
SA209783MM003_1_pE1exercise 1
SA209784MM026_1_pE1exercise 1
SA209785MM004_1_pE1exercise 1
SA209786MM027_3_pE1exercise 3
SA209787MM036_3_pE1exercise 3
SA209788MM022_3_pE1exercise 3
SA209789MM014_3_pE1exercise 3
SA209790MM026_3_pE1exercise 3
SA209791MM011_3_pE1exercise 3
SA209792MM004_3_pE1exercise 3
SA209793MM035_3_pE1exercise 3
SA209794MM003_3_pE1exercise 3
SA209795MM008_3_pE1exercise 3
SA209796MM010_3_pE1exercise 3
SA209698QC_HP_itMS2_CE0_it08MS2 MS2
SA209699QC_HP_itMS2_CE0_it07MS2 MS2
SA209700QC_HP_itMS2_CE0_it06MS2 MS2
SA209701QC_HP_itMS2_CE10_it01MS2 MS2
SA209702QC_HP_itMS2_CE10_it02MS2 MS2
SA209703QC_HP_itMS2_CE10_it04MS2 MS2
SA209704QC_HP_itMS2_CE10_it03MS2 MS2
SA209705QC_HP_itMS2_CE0_it05MS2 MS2
SA209706QC_HP_itMS2_CE0_it04MS2 MS2
SA209707QC_HP_itMS2_CE40_it06MS2 MS2
SA209708QC_HP_itMS2_CE40_it04MS2 MS2
SA209709QC_HP_itMS2_CE40_it08MS2 MS2
SA209710QC_HP_itMS2_CE40_it05MS2 MS2
SA209711QC_HP_itMS2_CE0_it01MS2 MS2
SA209712QC_HP_itMS2_CE0_it03MS2 MS2
SA209713QC_HP_itMS2_CE0_it02MS2 MS2
SA209714QC_HP_itMS2_CE10_it05MS2 MS2
SA209715QC_HP_itMS2_CE40_it07MS2 MS2
SA209716QC_HP_itMS2_CE20_it06MS2 MS2
SA209717QC_HP_itMS2_CE20_it05MS2 MS2
SA209718QC_HP_itMS2_CE20_it04MS2 MS2
SA209719QC_HP_itMS2_CE20_it07MS2 MS2
SA209720QC_HP_itMS2_CE20_it08MS2 MS2
SA209721QC_HP_itMS2_CE40_it02MS2 MS2
SA209722QC_HP_itMS2_CE40_it01MS2 MS2
SA209723QC_HP_itMS2_CE20_it03MS2 MS2
SA209724QC_HP_itMS2_CE40_it03MS2 MS2
SA209725QC_HP_itMS2_CE10_it07MS2 MS2
SA209726QC_HP_itMS2_CE10_it06MS2 MS2
SA209727QC_HP_itMS2_CE20_it01MS2 MS2
SA209728QC_HP_itMS2_CE10_it08MS2 MS2
SA209729QC_HP_itMS2_CE20_it02MS2 MS2
SA209730QC_HP_10QC QC
SA209731QC_HP_07QC QC
SA209732QC_HP_08QC QC
SA209733QC_HP_09QC QC
SA209734QC_HP_06QC QC
SA209735QC_HP_04QC QC
SA209736QC_HP_01QC QC
SA209737QC_HP_02QC QC
SA209738QC_HP_03QC QC
SA209739QC_HP_11QC QC
SA209740QC_HP_05QC QC
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 180

Collection:

Collection ID:CO002262
Collection Summary:Fasted plasma samples were collected from participants at multiple time points as depicted in Figure 1, taken from the protocol paper Nicol, J.L.;Woodrow, C.;Cunningham, B.J.; Mollee, P.;Weber, N.; Smith, M.D.; Nicol, A.J.; Gordon, L.G.; Hill, M.M.; Skinner, T.L. An Individualized Exercise Intervention for People with Multiple Myeloma—Study Protocol of a Randomized Waitlist-Controlled Trial. Curr. Oncol. 2022, 29, 901–923. https://doi.org/10.3390/curroncol29020077. After overnight fasting, plasma was collected by an experienced phlebotomist from an antecubital vein using a 23-gauge needle into EDTA-coated blood collection tubes and immediately stored on ice. Aliquots were prepared in Eppendorf tubes within 4 hours, and frozen at -80oC until use
Sample Type:Blood (plasma)

Treatment:

Treatment ID:TR002281
Treatment Summary:Multiple myeloma patients were randomized to exercise (EX) or waitlist (WT) groups as detailed in the protocol paper: Nicol, J.L.;Woodrow, C.;Cunningham, B.J.; Mollee, P.;Weber, N.; Smith, M.D.; Nicol, A.J.; Gordon, L.G.; Hill, M.M.; Skinner, T.L. An Individualized Exercise Intervention for People with Multiple Myeloma—Study Protocol of a Randomized Waitlist-Controlled Trial. Curr. Oncol. 2022, 29, 901–923. https://doi.org/10.3390/curroncol29020077. The individualized exercise program was for 3 months, and follow-up plasma was collected at 12 months. WT group had usual care for 3 months prior to the same exercise and follow-up regime

Sample Preparation:

Sampleprep ID:SP002275
Sampleprep Summary:In total, 126 human plasma samples from 46 patients were prepared. All samples (including QCs and blanks) were randomized in one batch and then evenly split between two 2 mL 96-deepwell plates (Eppendorf #0030 501.306). Human plasma samples were thawed on ice and briefly vortexed before aliquoting 100 µL plasma of each sample to a well. In addition, a global sample pool containing equal volumes (12 µL) of each sample was prepared into a 2 mL Eppendorf tube as quality control (QC) and 12 x 100 µL aliquots were transferred into wells across the 2 plates. Finally, blank negative control extraction samples were prepared by transferring 100 µL of 1X PBS to 6 wells equally across 2 plates. Ten-times the sample volume of ice-cold butanol/methanol (1:1) containing 50 µg/mL antioxidant 2,6-di-tert-butyl-4-methylphenol (BHT) and 0.5 µg/mL ISTD 4-chloro-L-phenylalanine (PCPA) was added to each well using a multi-channel pipette. Plates were covered with organic solvent resistant sealing mats (Eppendorf #0030 127.960) and vortexed for 3 min at 1000 rpm. Samples were then sonicated for 15 min in an ice-cold water bath sonicator, stored overnight at -30oC and centrifuged for 30 min at 4,000 x g (4oC). Samples were aliquoted into 96-well V-bottom plates (Greiner #651201) using a liquid handler platform (AssayMap Bravo, Agilent). From each deepwell plate, 4 x 100 µL and 2 x 200 µL aliquots were prepared, totalling 8 and 4 plates, respectively. Samples were dried down (2.5 hrs) using a Genevac EZ-2 vacuum concentrator and fast-stack swings facilitating drying of 8 plates per batch. Dried sample plates were covered with AlumaSeal CS sealing film for cold storage (Finneran-Porviar #FC-100) and stored at -80oC until LC/MS analysis

Chromatography:

Chromatography ID:CH002643
Chromatography Summary:Reversed-phase separation of metabolites was adapted from Evans et al. (2014) with modifications. Separation was achieved on a Zorbax Eclipse Plus C18 RRHD (1.8 μm, 95 Å, 2.1x50mm, #959757-902, Agilent) column held at 40°C and the MS was operated in positive ionization mode. Eluent A was milliQ water and eluent B was methanol both containing 0.1% formic acid. Total method runtime was 8.5 min with the following gradient: 0 min (0.5% eluent B) – 4 min (70% B) – 4.5 min (98% B) – 5.4 min (98% B) – 5.5 min (0.5% B) – 8.5 min (0.5% B). The flow was diverted to waste after 5 minutes and a flow rate of 0.4 mL/min was applied
Instrument Name:Agilent 1290 Infinity II
Column Name:Agilent ZORBAX RRHD Eclipse Plus C18 (50 x 2.1 mm,1.8 µm
Column Temperature:40
Flow Gradient:0 min (0.5% eluent B) - 4 min (70% B) - 4.5 min (98% B) - 5.4 min (98% B) - 5.5 min (0.5% B) - 8.5 min (0.5% B). The flow was diverted to waste after 5 minutes
Flow Rate:0.4 mL/min
Solvent A:100% water; 0.1% formic acid
Solvent B:100% methanol; 0.1% formic acid
Chromatography Type:Reversed phase
  
Chromatography ID:CH002644
Chromatography Summary:HILIC separation of metabolites was carried out on a Poroshell 120 HILIC-Z (100Å, 2.7µm, 2.1x100mm, #675775-924, Agilent) column at 30ºC and the MS was operated in negative ionization mode. Eluent A was 10 mM ammonium acetate and 5 μM medronic acid in ACN/milliQ 90:10 (pH 9) and eluent B was 10 mM ammonium acetate and 5 μM medronic acid in milliQ (pH 9). Gradient applied was: 0 min (10% eluent B) – 3.5 min (25% B) – 5.5 min (50% B) – 7.5 min (50% B) – 7.6 min (10% B) – 14 min (10% B). Flow rate was set to 0.25 mL/min with a flow ramp to 0.5 mL/min during equilibration
Instrument Name:Agilent 1290 Infinity II
Column Name:Agilent Poroshell 120 HILIC-Z (100 2.1mm,2.7um)
Flow Gradient:Gradient applied was: 0 min (10% eluent B) - 3.5 min (25% B) - 5.5 min (50% B) - 7.5 min (50% B) - 7.6 min (10% B) - 14 min (10% B).
Flow Rate:0.25 mL/min
Solvent A:90% acetonitrile/10% water; 10 mM ammonium acetate; 5 µM medronic acid, pH 9
Solvent B:100% water; 10 mM ammonium acetate; 5 µM medronic acid, pH 9
Chromatography Type:HILIC

Analysis:

Analysis ID:AN003575
Analysis Type:MS
Chromatography ID:CH002643
Has Rt:1
Rt Units:Minutes
Results File:ST002183_AN003575_Results.txt
Units:peak area
  
Analysis ID:AN003576
Analysis Type:MS
Chromatography ID:CH002644
Has Rt:1
Rt Units:Minutes
Results File:ST002183_AN003576_Results.txt
Units:peak area
  logo